Drugs / BI 3810944
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07224425 | Feb 2026 → Oct 2029 expected | cancer, melanoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3810944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07224425 ↗ |